‘They don't actually join the dots’: An exploration of organizational change in Irish opiate community treatment services

Autor: Peter, Kelly, Hegarty, J., R., Dyer Kyle, O Donovan, A.

Publikováno v: In Journal of Substance Abuse Treatment April 2022 135

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients

Autor: A. Visram, C. Soof, S. V. Rajkumar, S. K. Kumar, S. Bujarski, T. M. Spektor, R. A. Kyle, J. R. Berenson, A. Dispenzieri

Publikováno v: Blood Cancer Journal, Vol 11, Iss 6, Pp 1-7 (2021)

Abstract Soluble BCMA (sBCMA) levels are elevated in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the association between sBCMA levels and prognosis in MGUS and SMM has not been studied. We

Externí odkaz: https://doaj.org/article/968f228ca2df4749a131b3c805cfafd2

Widening the net: A syndemic approach to responsible gambling.

Autor: Nower, Lia¹ (AUTHOR) lnower@rutgers.edu, R. Caler, Kyle² (AUTHOR)

Publikováno v: Sucht. dez2018, Vol. 64 Issue 5/6, p317-323. 7p.

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Autor: C. Fernández de Larrea, R. A. Kyle, B. G. M. Durie, H. Ludwig, S. Usmani, D. H. Vesole, R. Hajek, J. F. San Miguel, O. Sezer, P. Sonneveld, S. K. Kumar, A. Mahindra, R. Comenzo, A. Palumbo, A. Mazumber, K. C. Anderson, P. G. Richardson, A. Z. Badros, J. Caers, X. LeLeu, M. A. Dimopoulos, C. S. Chim, R. Schots, A. Noeul, D. Fantl, U. H. Mellqvist, O. Landgren, A. Chanan Khan, P. Moreau, R. Fonseca, G. Merlini, J. J. Lahuerta, J. Bladé, R. Z. Orlowski, J. J. Shah, on behalf of the International Myeloma Working Group [, CAVO, MICHELE, ZAMAGNI, ELENA

Publikováno v: Leukemia, 27(4), 780-791. Nature Publishing Group
Fernández de Larrea, C, Kyle, R A, Durie, B G M, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Bladé, J, Orlowski, R Z, Shah, J J & International Myeloma Working Group 2013, ' Plasma cell leukemia : consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group ', Leukemia Insights, vol. 27, no. 4, pp. 780-91 . https://doi.org/10.1038/leu.2012.336
Digital.CSIC. Repositorio Institucional del CSIC
instname

PMCID: PMC4112539.-- International Myeloma Working Group: et al.
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2429b40fe6c5638ae3ea1bcf0c185f9
https://doi.org/10.1038/leu.2012.336

IgG Subclasses: Relationship to Clinical Aspects of Multiple Myeloma and Frequency Distribution among M-Components

Autor: S L Rivers, W J Hammack, R A Kyle, L Wolfson, R F Ritchie, O R McIntyre, K J Bloch, A Sargent, Peter H. Schur, William C. Moloney

Publikováno v: Scandinavian Journal of Haematology. 12:60-68

The possible role of IgG subclasses in patients with M-components or multiple myeloma was investigated. Among 900 patients with monoclonal proteins, the following IgG subclasses were identified: 77 % were IgG1; 14 % were IgG2; 6 % were IgG3; and 3 %

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56debaa3e966c02d56f88cca8393f85a
https://doi.org/10.1111/j.1600-0609.1974.tb00181.x